ZNTL Stock — Zentalis Pharmaceuticals Inc.: Cash, EV, Pipeline

What they do

We are a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), an investigational, potentially first-in-class and best-in-class WEE1 inhibitor, for patients with ovarian cancer and other tumor types. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types.

Source: 10-K FY2025 via SEC EDGAR

Share price

$1.72

Market cap

$162.8M

Cash

$199.4M

Enterprise value

-$36.6M

Balance sheet

Cash	$199.4M
Debt	$0.0M
Net cash	$199.4M
Enterprise value	-$36.6M
Basic shares	71.7M shares
Fully diluted shares	89.9M shares
Fully diluted market cap	$154.6M
Cash per share	$2.78
Quarterly burn	$37.2M
Cash runway	5.4 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

71.7M

Pre-funded warrants

0.0M

Options

15.3M

RSUs

2.9M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

—

FDSO

89.9M

Cap table as of 2026-06-30.

Price history

Loading ZNTL daily closes…

Loading price history…

Next catalyst

azenosertib · Est. Jan 12, 2027 · PCD + 6 wks · guided in 8 wks

Recently reported

Azenosertib Phase 2 Positive · 2026-10-18

GOG-3066

Primary: Overall survival (secondary endpoint) in platinum-resistant ovarian cancer patients treated with azenosertib monotherapy in DENALI Part 1b (GOG-3066), interim analysis — Median OS of 15.8 months (95% CI, 8.7-17.8) in the Cyclin E1-positive subgroup (n=48) versus 7.5 months (95% CI, 5.8-12.3) in the Cyclin E1-negative subgroup (n=46)

· Cyclin E1-positive subgroup: median OS 15.8 months (95% CI, 8.7-17.8), n=48

· Cyclin E1-negative subgroup: median OS 7.5 months (95% CI, 5.8-12.3), n=46

· 102 patients enrolled in Part 1b; 94 Cyclin E1-evaluable; azenosertib 400 mg QD 5:2 monotherapy

· Interim analysis, data cutoff September 2, 2025

· Azenosertib is a first-in-class WEE1 inhibitor, given as monotherapy

· Data published in ESMO Congress 2026 abstract; rapid oral presentation on October 23, 2026

Safety: No new safety signals were observed

Source release →

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Jan 12, 2027 in 8 wks PCD + 6 wks · Jan 1–Jan 26	azenosertib registration-intended DENALI Phase 2 of azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer	Phase 2	Cyclin E1-positive platinum-resistant ovarian cancer	H1 2027
Jul 12 - Aug 23 in 20 mo	Azenosertib	Phase 3	Ovarian Cancer	—
Aug 11 - Sep 22 in 21 mo	Azenosertib	Phase 1	Solid Tumor; Epithelial Ovarian Cancer; Fallopian Tube Cancer	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Azenosertib

Phase 3 · Active Modality: small molecule (WEE1 inhibitor)

Aliases ZN-c3

Target WEE1

Partnerships Recurium IP: exclusive worldwide license ($7.0M milestone paid in Q2 2026 upon commencement of ASPENOVA Phase 3; development/regulatory milestones up to $44.5M per product for first two indications; mid- to high-single-digit royalties)

Indications

Cyclin E1-positive platinum-resistant ovarian cancer (PROC) (Phase 2)
Solid tumors (in combination with chemotherapy regimens) (Phase 1)

Status note Only product candidate in clinical development. DENALI Part 2 could support accelerated approval; ASPENOVA Phase 3 confirmatory monotherapy commenced (Q2 2026); MUIR Phase 1b evaluating combination with chemotherapy regimens. FDA approval of a companion diagnostic is expected to be required for the lead indication.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Investigator's choice of Chemotherapy
Lead indication	Ovarian Cancer
Lead phase	Phase 3
Active trials	3
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07546500	Phase 3	Recruiting	Sponsor	ZNTL	—	Ovarian Cancer	—
NCT05128825	Phase 2	Recruiting	Sponsor	ZNTL	—	High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer	H1 2027 Est. Jan 12, 2027 · PCD + 6 wks (Jan 1-Jan 26) October 2026
NCT04516447	Phase 1	Recruiting	Sponsor	ZNTL	—	Solid Tumor; Epithelial Ovarian Cancer; Fallopian Tube Cancer	—
NCT06015659	Phase 2	Active, not recruiting	Collaborator	Brandon Huffman, MD	—	Advanced Pancreatic Adenocarcinoma; Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
OrbiMed Advisors	1,390,576	+1,390,576	0.13%	2026-08-14
ADAR1 Capital Management	652,750	+508,114	0.15%	2026-08-14
Stonepine Capital	161,583	-107,517	0.60%	2026-08-17

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

ZNTL — Zentalis Pharmaceuticals Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Recently reported

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

ZNTL — Zentalis Pharmaceuticals Inc.